District Court Decision Affirmed in U.S. Lovenox (enoxaparin sodium) Patent Infringement Case

PARIS, May 15, 2008 /PRNewswire-FirstCall/ -- Sanofi-aventis announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the February 8, 2007 decision by the U.S. District Court for the Central District of California in the sanofi-aventis Lovenox(R) patent infringement suit against Amphastar and Teva.

As a result of the Court of Appeals' ruling, the U.S. Lovenox(R) patent is deemed to be unenforceable.

Sanofi-aventis is considering all its legal options.

While several generic manufacturers have requested marketing approval from the FDA for their products alleged to be generic versions of Lovenox(R), sanofi-aventis has not learned of any FDA approval of these requests.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York .

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    CONTACT:  Jean-Marc Podvin

              sanofi-aventis

              +331-53-77-4223

              jeanmarc.podvin@sanofi-aventis.com

CONTACT: Jean-Marc Podvin, Vice President, Media Relations, sanofi-aventis, +331-53-77-4223, Charles F. Rouse III, sanofi-aventis, +1-908-243-6050

Web site: http://www.sanofi-aventis.us/http://www.sanofi-aventis.com/

Company News On-Call: http://www.prnewswire.com/comp/232375.html /

Ticker Symbol: (NYSE:SNY)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2008


View comments

Hide
(web1)